Current Cardiovascular Risk Reports

, Volume 1, Issue 5, pp 384–390

Cigarette smoking and cardiovascular disease



Data on the impact of smoking on mortality indicate that 35% of smoking-related deaths are due to cardiovascular causes. Current cigarette smoking is associated with a threefold to sixfold increase in risk of myocardial infarction and increased rates of ischemic stroke and subarachnoid hemorrhage. Tobacco smoking has the greatest deleterious effect on peripheral arteries, with multiple effects ranging from increased peripheral arterial disease and associated intermittent claudication, limb ischemia, and graft failure to a threefold or more increase in abdominal aortic aneurysm formation. The recent recognition of secondhand smoke as a risk factor for cardiovascular disease has led to governmental action to develop smoke-free public environments. Small communities with public smoking bans have already seen reductions in cardiovascular mortality.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hoyert D, Heron M, Murphy S, Kung H: Deaths: final data for 2003. Natl Vital Stat Rep 2006, 54:1–120.PubMedGoogle Scholar
  2. 2.
    Ranney L, Melvin C, Lux L, et al.: Tobacco Use: Prevention, Cessation, and Control. Evidence Report/Technology Assessment No. 140 (Prepared by the RTI International-University of North Carolina Evidence-Based Practice Center). Rockville, MD: Agency for Healthcare Research and Quality; 2006. AHRQ Publication No. 06-E015.Google Scholar
  3. 3.
    US Department of Health and Human Services: The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.Google Scholar
  4. 4.
    Barnoya J, Glantz SA: Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005, 111:2684–2698.PubMedCrossRefGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention (CDC): Tobacco use among adults—United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1145–1148.Google Scholar
  6. 6.
    Shibuya K, Ciecierski C, Guindon E, et al.: WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty. BMJ 2003, 327:154–157.PubMedCrossRefGoogle Scholar
  7. 7.
    Ambrose JA, Barua RS: The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004, 43:1731–1737.PubMedCrossRefGoogle Scholar
  8. 8.
    Neunteufl T, Heher S, Kostner K, et al.: Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol 2002, 39:251–256.PubMedCrossRefGoogle Scholar
  9. 9.
    Caralis DG, Deligonul U, Kern MJ, Cohen JD: Smoking is a risk factor for coronary spasm in young women. Circulation 1992, 85:905–909.PubMedGoogle Scholar
  10. 10.
    Allred EN, Bleecker ER, Chaitman BR, et al.: Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med 1989, 321:1426–1432.PubMedCrossRefGoogle Scholar
  11. 11.
    Blache D: Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol 1995, 268(2, Pt 2):H679–H685.PubMedGoogle Scholar
  12. 12.
    Zidovetzki R, Chen P, Fisher M, et al.: Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway. Stroke 1999, 30:651–655.PubMedGoogle Scholar
  13. 13.
    Barua RS, Ambrose JA, Saha DC, Eales-Reynolds LJ: Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002, 106:905–908.PubMedCrossRefGoogle Scholar
  14. 14.
    Fuster V, Gotto AM, Libby P, et al.: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 1996, 27:964–976.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishizaka N, Ishizaka Y, Toda E, et al.: Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis 2005, 181:381–388.PubMedCrossRefGoogle Scholar
  16. 16.
    Reaven G, Tsao PS: Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? J Am Coll Cardiol 2003, 41:1044–1047.PubMedCrossRefGoogle Scholar
  17. 17.
    Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363–369.PubMedCrossRefGoogle Scholar
  18. 18.
    Barua RS, Ambrose JA, Srivastava S, et al.: Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 2003, 107:2342–2347.PubMedCrossRefGoogle Scholar
  19. 19.
    Olin JW: Thromboangiitis pbliterans (Buerger’s disease). In Vascular Medicine: A Companion to Braunwald’s Heart Disease. Edited by Creager MA, Dzau V, Localzo J. Philadelphia: Saunders; 2006:641–656.Google Scholar
  20. 20.
    Lee AJ, Fowkes FG, Carson MN, et al.: Smoking, atherosclerosis and risk of abdominal aortic aneurysm. Eur Heart J 1997, 18:671–676.PubMedGoogle Scholar
  21. 21.
    Teo KK, Ounpuu S, Hawken S, et al.: Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006, 368:647–658.PubMedCrossRefGoogle Scholar
  22. 22.
    Price JF, Mowbray PI, Lee AJ, et al.: Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999, 20:344–353.PubMedCrossRefGoogle Scholar
  23. 23.
    Barbash GI, Reiner J, White HD, et al.: Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox” from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995, 26:1222–1229.PubMedCrossRefGoogle Scholar
  24. 24.
    Ruiz-Bailen M, de Hoyos EA, Reina-Toral A, et al.: Paradoxical effect of smoking in the Spanish population with acute myocardial infarction or unstable angina: results of the ARIAM Register. Chest 2004, 125:831–840.PubMedCrossRefGoogle Scholar
  25. 25.
    Critchley JA, Capewell S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Vlietstra RE, Kronmal RA, Oberman A, et al.: Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. Report from the CASS registry. JAMA 1986, 255:1023–1027.PubMedCrossRefGoogle Scholar
  27. 27.
    Centers for Disease Control (CDC): 1986 Surgeon General’s Report: the health consequences of involuntary smoking. MMWR Morb Mortal Wkly Rep 1986, 35:769–770.Google Scholar
  28. 28.
    Whincup PH, Gilg JA, Emberson JR, et al.: Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ 2004, 329:200–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Sargent RP, Shepard RM, Glantz SA: Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ 2004, 328:977–980.PubMedCrossRefGoogle Scholar
  30. 30.
    Lu JT, Creager MA: The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med 2004, 5:189–193.PubMedGoogle Scholar
  31. 31.
    Bartholomew JR, Olin JW: Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 2006, 73(Suppl 4):S8–S14.PubMedCrossRefGoogle Scholar
  32. 32.
    Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000, 1 (1, Pt 2):S1–S296.Google Scholar
  33. 33.
    Willigendael EM, Teijink JA, Bartelink ML, et al.: Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004, 40:1158–1165.PubMedCrossRefGoogle Scholar
  34. 34.
    Fowkes FG, Housley E, Riemersma RA, et al.: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992, 135:331–340.PubMedGoogle Scholar
  35. 35.
    Willigendael EM, Teijink JA, Bartelink ML, et al.: Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005, 42:67–74.PubMedCrossRefGoogle Scholar
  36. 36.
    Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF: Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997, 96:44–49.PubMedGoogle Scholar
  37. 37.
    Lederle FA, Johnson GR, Wilson SE, et al.: The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000, 160:1425–1430.PubMedCrossRefGoogle Scholar
  38. 38.
    Strachan DP: Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. Br J Surg 1991, 78:401–404.PubMedCrossRefGoogle Scholar
  39. 39.
    Wolf PA, D’Agostino RB, Kannel WB, et al.: Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988, 259:1025–1029.PubMedCrossRefGoogle Scholar
  40. 40.
    Kawachi I, Colditz GA, Stampfer MJ, et al.: Smoking cessation and decreased risk of stroke in women. JAMA 1993, 269:232–236.PubMedCrossRefGoogle Scholar
  41. 41.
    Smith SC, Jr, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363–2372.PubMedCrossRefGoogle Scholar
  42. 42.
    U.S. Preventive Services Task Force: Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med 2005, 142:198–202.Google Scholar
  43. 43.
    Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM: The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003, 163:1469–1474.PubMedCrossRefGoogle Scholar
  44. 44.
    Eason SL, Petersen NJ, Suarez-Almazor M, et al.: Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen? J Am Board Fam Pract 2005, 18:355–361.PubMedGoogle Scholar
  45. 45.
    Howard G, Wagenknecht LE, Burke GL, et al.: Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998, 279:119–124.PubMedCrossRefGoogle Scholar
  46. 46.
    Chambless LE, Folsom AR, Davis V, et al.: Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 2002, 155:38–47.PubMedCrossRefGoogle Scholar
  47. 47.
    Oren A, Vos LE, Uiterwaal CS, et al.: Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. Arch Intern Med 2003, 163:1787–1792.PubMedCrossRefGoogle Scholar
  48. 48.
    Anthonisen NR, Skeans MA, Wise RA, et al.: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233–239.PubMedGoogle Scholar
  49. 49.
    Ranney L, Melvin C, Lux L, et al.: Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med 2006, 145:845–856.PubMedGoogle Scholar
  50. 50.
    Richmond RL, Kehoe L, de Almeida Neto AC: Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch. Heart 1997, 78:617–618.PubMedGoogle Scholar
  51. 51.
    Daughton DM, Fortmann SP, Glover ED, et al.: The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 1999, 28:113–118.PubMedCrossRefGoogle Scholar
  52. 52.
    Jorenby DE, Leischow SJ, Nides MA, et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340:685–691.PubMedCrossRefGoogle Scholar
  53. 53.
    Gonzales D, Rennard SI, Nides M, et al.: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47–55.PubMedCrossRefGoogle Scholar
  54. 54.
    Jorenby DE, Hays JT, Rigotti NA, et al.: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56–63.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Cleveland ClinicClevelandUSA

Personalised recommendations